Morabito F, Tomaino A, Cristani M, Martino M, Minciullo P L, Saija A, Gangemi S
Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Transfus Med. 2005 Oct;15(5):425-8. doi: 10.1111/j.1365-3148.2005.00605.x.
Administration of granulocyte colony-stimulating factor (G-CSF) is widely used for harvesting an adequate number of CD34+ stem cells by leukapheresis in normal donors. G-CSF is the most established agent for the mobilization of stem cells in current clinical practice, because it has been proven to be superior to any other agent tested to date in terms of not only mobilization capacity, but also of tolerance. However, although regulatory and accrediting agencies have provided guidelines to protect donors, the short- and long-term side effects of G-CSF need to be further studied. In this study, we evaluated the time course of plasma myeloperoxidase (MPO) levels measured in a group of donors given recombinant human G-CSF (rHuG-CSF) at different intervals: (i) before starting rHuG-CSF administration, (ii) on day 5 of rHuG-CSF administration, (iii) on the same day soon after the end of the first leukapheresis procedure and (iv) 1 week after rHuG-CSF withdrawal. Plasma MPO levels significantly increased in the donors after 5 days of rHuG-CSF treatment, returning to the baseline values within 7 days following rHuG-CSF withdrawal. These findings may contribute to a better understanding of G-CSF safety profile in stem cell donors.
在正常供体中，使用粒细胞集落刺激因子（G-CSF）通过白细胞分离术采集足够数量的CD34+干细胞已被广泛应用。在当前临床实践中，G-CSF是用于动员干细胞的最成熟药物，因为它已被证明在动员能力和耐受性方面均优于迄今为止测试的任何其他药物。然而，尽管监管和认证机构已提供保护供体的指南，但G-CSF的短期和长期副作用仍需进一步研究。在本研究中，我们评估了一组在不同时间间隔给予重组人G-CSF（rHuG-CSF）的供体血浆髓过氧化物酶（MPO）水平的时间进程：（i）开始rHuG-CSF给药前，（ii）rHuG-CSF给药第5天，（iii）第一次白细胞分离术结束后当天，以及（iv）rHuG-CSF停药1周后。rHuG-CSF治疗5天后，供体血浆MPO水平显著升高，在rHuG-CSF停药后7天内恢复至基线值。这些发现可能有助于更好地了解干细胞供体中G-CSF的安全性。
